Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHI-554 in Postmenopausal Women With Osteopenia
NCT05317013Phase 1Terminated
- Sponsor
- C³ Cannabinoid Compound Company
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabidiol in osteopenia (3 arms), sponsored by C³ Cannabinoid Compound Company. Primary endpoints: Adverse Events/Serious Adverse Events at Week 12, Alanine aminotransferase at Week 12 and 4 more. Started May 2022; status: terminated.
02
Drugs
cannabidiol
03
Conditions
osteopenia
Beyond the preview
Go deeper on NCT05317013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05317013.